Excision BioTherapeutics, Inc.

Human immunodeficiency virus (HIV)

Herpes simplex viruses (HSV 1&2)

Hepatitis B

Latest News

Dec 3, 2024

Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit

Sep 16, 2024

Presentation at the 2024 International HBV Meeting Highlights Antiviral Activity of EBT-107 as a Potential Anti-HBV Therapy

Sep 9, 2024

Excision BioTherapeutics Announces Oral Presentation at the 2024 International HBV Meeting

View All News

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

Robert Gallo, M.D., University of Maryland, Co-discoverer of HIV

Referring to Excision’s technology and work in the Khalili lab

"I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much-needed therapies to those in need around the world."

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

"For the first time, researchers eliminated HIV from the genomes of living animals."

TIME, 2019

Alice Park review of Excision’s technology publication in Nature Medicine, July 2019

"A new reason for increased hope that an actual cure may ultimately be found."

Francis Collins, M.D. Ph.D., NIH Director

In a review of Excision’s technology on the NIH website, 2019

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

Robert Gallo, M.D., University of Maryland, Co-discoverer of HIV

Referring to Excision’s technology and work in the Khalili lab

"I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much-needed therapies to those in need around the world."

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

"For the first time, researchers eliminated HIV from the genomes of living animals."

TIME, 2019

Alice Park review of Excision’s technology publication in Nature Medicine, July 2019

"A new reason for increased hope that an actual cure may ultimately be found."

Francis Collins, M.D. Ph.D., NIH Director

In a review of Excision’s technology on the NIH website, 2019

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

Robert Gallo, M.D., University of Maryland, Co-discoverer of HIV

Referring to Excision’s technology and work in the Khalili lab

Helping Patients Break Free from Viral Diseases

Founded in 2015, Excision BioTherapeutics is a biotechnology company leveraging proprietary, CRISPR-based gene-editing technology and collaborative partnerships with leading research institutions to develop and advance transformative therapies designed to improve the lives of patients living with viral infectious diseases.--

About Our Company

Focused on Cures

Cutting-edge Therapies Designed to Eliminate Viral DNA

Human immunodeficiency virus (HIV)

Herpes simplex viruses (HSV 1&2)

Hepatitis B

Latest News

Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit

Presentation at the 2024 International HBV Meeting Highlights Antiviral Activity of EBT-107 as a Potential Anti-HBV Therapy

Excision BioTherapeutics Announces Oral Presentation at the 2024 International HBV Meeting

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

"I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much-needed therapies to those in need around the world."

"For the first time, researchers eliminated HIV from the genomes of living animals."

"A new reason for increased hope that an actual cure may ultimately be found."

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

"I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much-needed therapies to those in need around the world."

"For the first time, researchers eliminated HIV from the genomes of living animals."

"A new reason for increased hope that an actual cure may ultimately be found."

"This may be a breakthrough... Such molecular biological approaches will be the future for a bona fide approach to HIV eradication and merits maximum support."

Helping Patients Break Free from Viral Diseases

Join Excision